Biopharmaceutical company argenx SE (ARGX) Monday said preliminary global revenues for its only approved product VYVGART for the treatment of generalized myasthenia gravis (gMG), is expected to be about $374 million for the fourth quarter.
Full-year revenue for VYVGART is expected at $1.2 billion.
As of December 31, 2023, argenx had approximately $3.2 billion in cash, cash equivalents and current financial assets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.